Mendus
Clinical-stage company developing immunotherapies to prevent tumor recurrence.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
Description
Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-30 08:00 |
Change in Number of Shares and Votes in Immunicum AB (publ)
|
English | PDF • 96.5 KB | ||
| 2020-12-30 08:00 |
Förändring av antal aktier och röster i Immunicum AB (publ)
|
Swedish | PDF • 96.0 KB | ||
| 2020-12-29 08:00 |
Changes to the Nomination Committee for Immunicum AB (publ)
|
English | PDF • 79.1 KB | ||
| 2020-12-29 08:00 |
Ändringar i valberedningen för Immunicum AB (publ)
|
Swedish | PDF • 79.4 KB | ||
| 2020-12-22 10:18 | English | PDF • 34.1 KB | |||
| 2020-12-21 16:05 |
Kallelse till extra bolagsstämma i Immunicum AB (publ)
|
Swedish | PDF • 120.2 KB | ||
| 2020-12-21 16:05 |
Notice of Extraordinary General Meeting in Immunicum AB (publ)
|
English | PDF • 123.4 KB | ||
| 2020-12-21 16:00 |
Immunicum AB (publ) Completes Business Combination with DCprime
|
English | PDF • 103.2 KB | ||
| 2020-12-21 16:00 |
Immunicum AB (publ) slutför sammanslagningen med DCprime
|
Swedish | PDF • 102.8 KB | ||
| 2020-12-18 15:30 |
Immunicum AB (publ) offentliggör prospekt avseende upptagande till handel av ny…
|
Swedish | PDF • 875.1 KB | ||
| 2020-12-18 15:30 |
Immunicum AB (publ) Publishes Prospectus for Admission to Trading of Newly Issu…
|
English | PDF • 98.2 KB | ||
| 2020-12-18 14:00 |
Report from the Extraordinary General Meeting of Immunicum AB (publ) on Decembe…
|
English | PDF • 78.8 KB | ||
| 2020-12-18 14:00 |
Kommuniké från extra bolagsstämma i Immunicum AB (publ) den 18 december 2020
|
Swedish | PDF • 76.0 KB | ||
| 2020-12-16 11:30 |
Immunicum AB (publ) publicerar finansiell kalender 2021
|
Swedish | PDF • 93.8 KB | ||
| 2020-12-16 11:30 |
Immunicum AB (publ) Publishes Financial Calendar 2021
|
English | PDF • 74.8 KB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 56,249.40 SEK |
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 55,704.80 SEK |
| 2025-02-25 | Sven Arne Andreasson | Other | Buy | 25,000 | 198,750.00 SEK |
| 2024-04-02 | Erik Manting | Other | Other | 885,648 | 425,111.04 SEK |
| 2024-04-02 | Dharminder Chahal | Other | Other | 882,048 | 423,383.04 SEK |
| 2024-04-02 | Leopold Bertea | Other | Other | 267,858 | 128,571.84 SEK |
| 2022-10-25 | Sven Arne Andreasson | Other | Sell | 15,000 | 31,950.00 SEK |
| 2022-10-12 | Sven Arne Andreasson | Other | Sell | 10,000 | 18,800.00 SEK |
| 2022-05-20 | Erik Manting | Other | Buy | 37,059 | 86,347.47 SEK |
| 2022-05-19 | Ann-Charlotte Ferm | Other | Buy | 100,000 | 215,900.00 SEK |
Peer Companies
